Status:
COMPLETED
Mineralocorticoid Receptor and Obesity Induced Cardiovascular Complications
Lead Sponsor:
Brigham and Women's Hospital
Conditions:
Obesity
Insulin Resistance
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
The purpose of this study is to find out if spironolactone, a drug that blocks the action of aldosterone, can make the blood vessels work better in people with obesity. The investigators also want to ...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Age 18-70 years
- Good health as evidenced by history and physical exam
- Body Mass Index (BMI): \>30 kg/m2 and \<45 kg/m2
- Exclusion criteria:
- Medical illnesses other than treated hypothyroidism
- Blood Pressure (BP) \>135/85 or systolic BP \<90 mm Hg
- Hepatic disease (transaminase \> 3 times normal)
- Renal impairment (Creatinine clearance \<60 ml/min)
- Baseline serum Potassium (K) \>5.0 mmol/L
- History of drug or alcohol abuse
- Allergies to spironolactone
- Participation in any other concurrent clinical trial
- Women using oral contraceptives within the last 3 months
Exclusion
Key Trial Info
Start Date :
February 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2013
Estimated Enrollment :
38 Patients enrolled
Trial Details
Trial ID
NCT01406015
Start Date
February 1 2009
End Date
December 1 2013
Last Update
April 28 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115